Objective: To determine the impact of earlier ureteral ligation (EUL) during hand-assisted retroperitoneoscopic nephroureterectomy (HARN) for primary renal pelvis urothelial cancer. Methods: We retrospectively reviewed 240 patients with upper urinary tract urothelial cancer who underwent HARN. Only patients with primary renal pelvis urothelial cancer and complete follow-up with a minimum of 1 year after HARN were enrolled into our study. We defined EUL as ligating the ureter prior to pneumoretroperitoneum and mobilizing the kidney during the surgery. Of these 61 patients, 31 (who composed the study group) underwent EUL, while 30 serving as controls were without ureteral ligation during the surgery. We analyzed intravesical recurrence utilizing log rank testing to assess the significance between the two groups. Results: Clinical parameters were similar between the two groups. The median follow-up after HARN was 39.7 months (range 12-96). There was no significant difference in the rate of intravesical recurrence and cancer-specific survival. However, patients without ligation of the ureter had shorter time to first bladder tumor recurrence (11.7 ± 9.1 months vs. 26.4 ± 19.1 months, p = 0.03). Conclusion: EUL during HARN for primary renal urothelial cancer did not affect intravesical recurrence rate or cancer-specific survival.

Keywords:
Laparoscopy, Nephrectomy, Retroperitoneal, Transitional cell carcinoma, Renal pelvis, Bladder cancer
1.
Landman J, Lev RY, Bhayani S, et al: Comparison of hand assisted and standard laparoscopic radical nephroureterectomy for the management of localized transitional cell carcinoma. J Urol 2002;167:2387-2391.
2.
Hsueh TY, Huang YH, Chiu AW, et al: Survival analysis in patients with upper urinary tract transitional cell carcinoma: a comparison between open and hand-assisted laparoscopic nephroureterectomy. BJU Int 2007;99:632-636.
3.
Berger A, Haber GP, Kamoi K, et al: Laparoscopic radical nephroureterectomy for upper tract transitional cell carcinoma: oncological outcomes at 7 years. J Urol 2008;180:849-854.
4.
Ou CH, Yang WH: Hand assisted retroperitoneoscopic nephroureterectomy with the patient spread-eagled: an approach through a completely supine position. J Urol 2008;180:1918-1921.
5.
Catto JW, Hartmann A, Stoehr R, et al: Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require pan-urothelial treatment for tumor clearance. J Urol 2006;175:2323-2330.
6.
Kang CH, Yu TJ, Hsieh HH, et al: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer 2003;98:1620-1626.
7.
Azémar MD, Comperat E, Richard F, et al: Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol 2011;29:130-136.
8.
Hisataki T, Miyao N, Masumori N, et al: Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology 2000;55:663-667.
9.
Kume H, Teramoto S, Tomita K, et al: Bladder recurrence of upper urinary tract cancer after laparoscopic surgery. J Surg Oncol 2006;93:318-322.
10.
Matsui Y, Utsunomiya N, Ichioka K, et al: Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 2005;65:279-283.
11.
Li CC, Chang TH, Wu WJ, et al: Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur Urol 2008;54:1127-1134.
12.
van der Poel HG, Antonini N, van Tinteren H, et al: Upper urinary tract cancer: location is correlated with prognosis. Eur Urol 2005;48:438-444.
13.
Park S, Hong B, Kim CS, et al: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 2004;171:621-625.
14.
Margulis V, Shariat SF, Matin SF, et al: Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224-1233.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.